Insmed Incorporated (0JAV.L)
USD 72.6
(0.07%)
USD 72.6
(0.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 949.26 Million USD | 37.74% |
| 2022 | 668.35 Million USD | 30.52% |
| 2021 | 512.06 Million USD | 31.38% |
| 2020 | 389.77 Million USD | 12.16% |
| 2019 | 347.5 Million USD | 10.41% |
| 2018 | 314.75 Million USD | 66.6% |
| 2017 | 188.92 Million USD | 8.95% |
| 2016 | 173.4 Million USD | 47.58% |
| 2015 | 117.49 Million USD | 34.49% |
| 2014 | 87.36 Million USD | 31.35% |
| 2013 | 66.51 Million USD | 56.73% |
| 2012 | 42.43 Million USD | 5.71% |
| 2011 | 40.14 Million USD | 167.41% |
| 2010 | 15.01 Million USD | -21.18% |
| 2009 | 19.04 Million USD | -27.05% |
| 2008 | 26.11 Million USD | -4.68% |
| 2007 | 27.39 Million USD | -49.16% |
| 2006 | 53.87 Million USD | 95.44% |
| 2005 | 27.56 Million USD | 0.01% |
| 2004 | 27.56 Million USD | 156.73% |
| 2003 | 10.73 Million USD | -70.54% |
| 2002 | 36.44 Million USD | -9.97% |
| 2001 | 40.48 Million USD | 29.91% |
| 2000 | 31.16 Million USD | 250.91% |
| 1999 | 8.87 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 253.31 Million USD | 18.27% |
| 2024 Q1 | 214.18 Million USD | -5.99% |
| 2024 Q3 | 285.68 Million USD | 12.78% |
| 2023 Q2 | 282.66 Million USD | 35.22% |
| 2023 Q4 | 227.82 Million USD | 13.32% |
| 2023 Q3 | 201.03 Million USD | -28.88% |
| 2023 FY | 920.56 Million USD | 37.74% |
| 2023 Q1 | 209.04 Million USD | 4.78% |
| 2022 Q1 | 142.36 Million USD | -0.36% |
| 2022 FY | 668.35 Million USD | 30.52% |
| 2022 Q4 | 199.5 Million USD | 9.65% |
| 2022 Q3 | 181.95 Million USD | 32.68% |
| 2022 Q2 | 137.14 Million USD | -3.67% |
| 2021 FY | 512.06 Million USD | 31.38% |
| 2021 Q3 | 131.89 Million USD | 7.15% |
| 2021 Q4 | 142.88 Million USD | 8.33% |
| 2021 Q2 | 123.09 Million USD | 7.79% |
| 2021 Q1 | 114.2 Million USD | -8.7% |
| 2020 Q3 | 89.24 Million USD | 2.98% |
| 2020 Q1 | 88.77 Million USD | 5.58% |
| 2020 Q4 | 125.09 Million USD | 40.17% |
| 2020 Q2 | 86.65 Million USD | -2.39% |
| 2020 FY | 389.77 Million USD | 12.16% |
| 2019 Q2 | 87.21 Million USD | -0.05% |
| 2019 Q4 | 84.08 Million USD | -5.46% |
| 2019 FY | 347.5 Million USD | 10.41% |
| 2019 Q3 | 88.93 Million USD | 1.97% |
| 2019 Q1 | 87.26 Million USD | -8.28% |
| 2018 Q2 | 72.88 Million USD | 16.14% |
| 2018 Q1 | 62.75 Million USD | -3.98% |
| 2018 FY | 314.75 Million USD | 66.6% |
| 2018 Q4 | 95.13 Million USD | 13.28% |
| 2018 Q3 | 83.98 Million USD | 15.23% |
| 2017 FY | 188.92 Million USD | 8.95% |
| 2017 Q1 | 35.96 Million USD | -46.36% |
| 2017 Q4 | 65.35 Million USD | 48.25% |
| 2017 Q2 | 43.51 Million USD | 20.98% |
| 2017 Q3 | 44.08 Million USD | 1.31% |
| 2016 Q4 | 67.05 Million USD | 80.49% |
| 2016 Q3 | 37.14 Million USD | 2.81% |
| 2016 FY | 173.4 Million USD | 47.58% |
| 2016 Q1 | 33.06 Million USD | 1.46% |
| 2016 Q2 | 36.13 Million USD | 9.27% |
| 2015 Q3 | 30.24 Million USD | 8.2% |
| 2015 Q1 | 26.7 Million USD | 15.78% |
| 2015 Q4 | 32.59 Million USD | 7.75% |
| 2015 FY | 117.49 Million USD | 34.49% |
| 2015 Q2 | 27.95 Million USD | 4.67% |
| 2014 Q2 | 22.81 Million USD | 26.2% |
| 2014 Q4 | 23.06 Million USD | -1.44% |
| 2014 FY | 87.36 Million USD | 31.35% |
| 2014 Q1 | 18.07 Million USD | 15.94% |
| 2014 Q3 | 23.4 Million USD | 2.58% |
| 2013 Q1 | 14.3 Million USD | -9.65% |
| 2013 FY | 66.51 Million USD | 56.73% |
| 2013 Q4 | 15.59 Million USD | -7.41% |
| 2013 Q3 | 16.84 Million USD | -14.81% |
| 2013 Q2 | 19.76 Million USD | 38.16% |
| 2012 Q2 | 9.98 Million USD | 37.43% |
| 2012 Q1 | 7.26 Million USD | -29.29% |
| 2012 FY | 42.43 Million USD | 5.71% |
| 2012 Q4 | 15.83 Million USD | 69.34% |
| 2012 Q3 | 9.35 Million USD | -6.31% |
| 2011 FY | 40.14 Million USD | 167.41% |
| 2011 Q2 | 11.45 Million USD | 27.01% |
| 2011 Q1 | 9.01 Million USD | 17.84% |
| 2011 Q3 | 9.4 Million USD | -17.87% |
| 2011 Q4 | 10.27 Million USD | 9.23% |
| 2010 Q1 | 2.18 Million USD | 1.63% |
| 2010 Q4 | 7.65 Million USD | 218.13% |
| 2010 FY | 15.01 Million USD | -21.18% |
| 2010 Q2 | 2.77 Million USD | 27.39% |
| 2010 Q3 | 2.4 Million USD | -13.4% |
| 2009 Q4 | 2.14 Million USD | -33.78% |
| 2009 FY | 19.04 Million USD | -27.05% |
| 2009 Q2 | 4.34 Million USD | -53.35% |
| 2009 Q1 | 9.31 Million USD | 41.23% |
| 2009 Q3 | 3.23 Million USD | -25.47% |
| 2008 Q4 | 6.59 Million USD | 10.74% |
| 2008 Q2 | 7.08 Million USD | -0.45% |
| 2008 Q3 | 5.95 Million USD | -15.9% |
| 2008 Q1 | 7.11 Million USD | 29.69% |
| 2008 FY | 26.11 Million USD | -4.68% |
| 2007 Q4 | 5.48 Million USD | -1.6% |
| 2007 Q3 | 5.57 Million USD | 15.09% |
| 2007 Q2 | 4.84 Million USD | -57.83% |
| 2007 Q1 | 11.48 Million USD | -45.48% |
| 2007 FY | 27.39 Million USD | -49.16% |
| 2006 Q3 | 12.31 Million USD | 29.52% |
| 2006 Q2 | 9.51 Million USD | -13.33% |
| 2006 Q1 | 10.97 Million USD | 54.83% |
| 2006 Q4 | 21.07 Million USD | 71.04% |
| 2006 FY | 53.87 Million USD | 95.44% |
| 2005 Q1 | 5.58 Million USD | -5.52% |
| 2005 Q2 | 6.97 Million USD | 25.07% |
| 2005 FY | 27.56 Million USD | 0.01% |
| 2005 Q3 | 7.91 Million USD | 13.45% |
| 2005 Q4 | 7.08 Million USD | -10.48% |
| 2004 Q2 | 9.08 Million USD | 85.64% |
| 2004 Q1 | 4.89 Million USD | 93.44% |
| 2004 FY | 27.56 Million USD | 156.73% |
| 2004 Q3 | 7.67 Million USD | -15.6% |
| 2004 Q4 | 5.9 Million USD | -23.01% |
| 2003 Q1 | 2.36 Million USD | -87.33% |
| 2003 FY | 10.73 Million USD | -70.54% |
| 2003 Q4 | 2.53 Million USD | 1.44% |
| 2003 Q3 | 2.49 Million USD | -25.46% |
| 2003 Q2 | 3.34 Million USD | 41.64% |
| 2002 Q1 | 6.41 Million USD | -37.75% |
| 2002 Q2 | 7.34 Million USD | 14.63% |
| 2002 FY | 36.44 Million USD | -9.97% |
| 2002 Q4 | 18.65 Million USD | 362.09% |
| 2002 Q3 | 4.03 Million USD | -45.08% |
| 2001 FY | 40.48 Million USD | 29.91% |
| 2001 Q4 | 10.29 Million USD | 13.93% |
| 2001 Q3 | 9.04 Million USD | -6.78% |
| 2001 Q2 | 9.69 Million USD | -15.26% |
| 2001 Q1 | 11.44 Million USD | 127.26% |
| 2000 FY | 31.16 Million USD | 250.91% |
| 2000 Q4 | -41.98 Million USD | -809.51% |
| 2000 Q3 | 5.91 Million USD | -89.38% |
| 2000 Q1 | 11.53 Million USD | 0.0% |
| 2000 Q2 | 55.69 Million USD | 382.95% |
| 1999 Q1 | 1.74 Million USD | 0.0% |
| 1999 FY | 8.87 Million USD | 0.0% |
| 1999 Q2 | 1.91 Million USD | 9.38% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 45.641% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -7718.639% |
| Myriad Genetics, Inc. | 600.1 Million USD | -58.184% |
| Evolus, Inc. | 189.75 Million USD | -400.246% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -21.765% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 55.118% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -132.203% |
| uniQure N.V. | 285.08 Million USD | -232.974% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1602.527% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -244.318% |
| bluebird bio, Inc. | 240.23 Million USD | -295.143% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1857.158% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 47.265% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -157.523% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -121.971% |
| Dynavax Technologies Corporation | 219.14 Million USD | -333.166% |
| Editas Medicine, Inc. | 247.3 Million USD | -283.844% |
| FibroGen, Inc. | 398.11 Million USD | -138.44% |
| Geron Corporation | 70.44 Million USD | -1247.597% |
| Blueprint Medicines Corporation | 722.86 Million USD | -31.32% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 53.762% |
| Illumina, Inc. | 3.81 Billion USD | 75.105% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -110.482% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -2324.491% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 40.541% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -566.321% |
| Adicet Bio, Inc. | 152.03 Million USD | -524.358% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 30.243% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -72.103% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 12.863% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2025.195% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -79.441% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 97.662% |
| Waters Corporation | 943.51 Million USD | -0.609% |
| Zoetis Inc. | 2.76 Billion USD | 65.669% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 90.743% |
| Biogen Inc. | 5.2 Billion USD | 81.762% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -315.105% |
| Nektar Therapeutics | 190.9 Million USD | -397.248% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -841.475% |
| Perrigo Company plc | 1.52 Billion USD | 37.896% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -99.274% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -686.743% |
| Verastem, Inc. | 92.08 Million USD | -930.864% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 80.12% |
| Imunon, Inc. | 21.03 Million USD | -4413.75% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -6724.482% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -249.125% |
| Homology Medicines, Inc. | 9.87 Million USD | -9512.77% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 66.282% |
| OPKO Health, Inc. | 574.68 Million USD | -65.179% |
| Exelixis, Inc. | 1.58 Billion USD | 40.177% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -217.141% |
| TG Therapeutics, Inc. | 198.47 Million USD | -378.277% |
| Incyte Corporation | 1.19 Billion USD | 20.263% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 9.075% |